Lenalidomide in multiple myeloma: current role and future directions

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20
   PubMed Web of Science ®Google Scholar
• Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002;2:175-87
   PubMed Web of Science ®Google Scholar
• Tonon G. Molecular pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 2007;21:985-1006
   PubMed Web of Science ®Google Scholar
• International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Kyle RA. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2005;80:1371-82
   PubMed Web of Science ®Google Scholar
• Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma. Version 2.2010. Available from: http://www.nccn.org [Last accessed 7 September 2009]
   Google Scholar
• Dimopoulos M, Spencer A, Attal M, Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32
   PubMed Web of Science ®Google Scholar
• Weber D, Chen C, Niesvizky R, Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-42
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J, Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-65
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee BN, Schlette EJ, Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291-7
   PubMed Web of Science ®Google Scholar
• Wiernik P, Lossos IS, Justice G, Preliminary results from a phase II study of lenalidomide monotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma. Presented at the 11th Congress of the European Hematology Association; 2006: abstract 0706
   Google Scholar
• Witzig TE, Vose JM, Kaplan HP, Early results from a phase II study of lenalidomide monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma. Blood 2006;108:703a: abstract 2482
   Google Scholar
• Revlimid® (lenalidomide) prescribing information. Summit, NJ: Celgene Corporation, January 2009. Available from: http://www.revlimid.com/pdf/REVLIMID_PI.pdf [Last accessed 7 September 2009]
   Google Scholar
• Hideshima T, Chauhan D, Shima Y, Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-50
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525-30
   PubMed Web of Science ®Google Scholar
• Verhelle D, Corral LG, Wong K, Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007;67:746-55
   PubMed Web of Science ®Google Scholar
• Gupta D, Treon SP, Shima Y, Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001;15:1950-61
   PubMed Web of Science ®Google Scholar
• Richardson PG, Schlossman RL, Weller E, Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7
   PubMed Web of Science ®Google Scholar
• Corral LG, Haslett PA, Muller GW, Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-6
   PubMed Web of Science ®Google Scholar
• Dredge K, Horsfall R, Robinson SP, Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005;69:56-63
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-16
   PubMed Web of Science ®Google Scholar
• Marriott JB, Clarke IA, Dredge K, Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells. Clin Exp Immunol 2002;130:75-84
   PubMed Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC, The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58:1033-45
   PubMed Web of Science ®Google Scholar
• Chauhan D, Hideshima T, Rosen S, Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J Biol Chem 2001;276:24453-6
   PubMed Web of Science ®Google Scholar
• Chen N, Lau H, Kong L, Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007;47:1466-75
   PubMed Web of Science ®Google Scholar
• Wang M, Dimopoulos MA, Chen C, Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008;112:4445-51
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Yu Z, Weber D, Lenalidomide (L) in combination with dexamethasone (D) significantly improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM): analysis from MM-009 and MM-010 randomized phase III clinical trials. ASH Annual Meeting Abstracts. Blood 2006;108: abstract 3554
   Google Scholar
• Dimopoulos MA, Chen C, Spencer A, Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009: published online 23 July 2009, doi: 10.1038/leu.2009.147
   Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892-901
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71
   PubMed Web of Science ®Google Scholar
• Harousseau J-L, Weber D, Dimopoulos M, Relapsed/refractory multiple myeloma patients treated with lenalidomide/dexamethasone who achieve a complete or near complete response have a longer overall survival and time to progression compared with patients achieving a partial response. ASH Annual Meeting Abstracts. Blood 2007;110: abstract 3598
   Google Scholar
• San Miguel J, Dimopoulos M, Bravo M-L, Weber D. Longer duration of treatment and maintenance of best response with lenalidomide + dexamethasone increases overall survival (OS) in patients with relapsed/refractory multiple myeloma. Haematologica 2009;94(Suppl 2):382: abstract 0949
   Google Scholar
• Dimopoulos M, Hussein M, Swern A, Full dose of lenalidomide for 12 months followed by a lower maintenance dose improves progression-free survival in patients with relapsed/refractory multiple myeloma. Poster presented at the 51st ASH Annual Meeting, New Orleans, Louisiana, USA, 5 – 8 December 2009
   Google Scholar
• Stadtmauer EA, Weber DM, Niesvizky R, Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol 2009;82:426-32
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Gertz MA, Dispenzieri A, Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007;82:1179-84
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Hayman SR, Lacy MQ, Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-3
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29-37
   PubMed Web of Science ®Google Scholar
• Zonder JA, Crowley J, Hussein MA, Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG Trial S0232. ASH Annual Meeting Abstracts. Blood 2007;110: abstract 77
   Google Scholar
• Mazumder A, Kaufman J, Niesvizky R, Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008;22:1280-1
   PubMed Web of Science ®Google Scholar
• Paripati H, Stewart AK, Fonseca R, Impact of lenalidomide therapy on stem cell mobilization in myeloma. ASCO Meeting Abstracts. J Clin Oncol 2008;26(Suppl): abstract 8543
   Google Scholar
• Cook RJ, Vogl D, Mangan PA, Lenalidomide and stem cell collection in patients with multiple myeloma. ASCO Meeting Abstracts. J Clin Oncol 2008;26(Suppl): abstract 8547
   PubMedGoogle Scholar
• Kumar S, Dispenzieri A, Lacy MQ, Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007;21:2035-42
   PubMed Web of Science ®Google Scholar
• Mark T, Stern J, Furst JR, Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transpl 2008;14:795-8
   PubMed Web of Science ®Google Scholar
• Popat U, Saliba R, Thandi R, Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009;15:718-23
   PubMed Web of Science ®Google Scholar
• Kumar S, Giralt S, Stadtmauer EA, Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009;114:1729-35
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Christoulas D, Treatment of patients with relapsed/refractory multiple myeloma (MM) with lenalidomide and dexamethasone with or with bortezomib depending on prior neurotoxicity: prospective evaluation of the impact of cytogenetic abnormalities and assessment of bone met. ASH Annual Meeting Abstracts. Blood 2008;112: abstract 1726
   Google Scholar
• Richardson P, Jagannath S, Raje N, Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): preliminary results of a phase II study. ASH Annual Meeting Abstracts. Blood 2007;110: abstract 2714
   Google Scholar
• Ruckser R, Tatzreiter G, Kitzweger E, Combination therapy with lenalidomide, bortezomib, liposomal doxorubicin and dexamethasone (LBlipDD) may overcome resistance to prior treatment with doxorubicin, lenalidomide, and bortezomib in high-risk multiple myeloma (MM). ASH Annual Meeting Abstracts. Blood 2007;110:abstract 4838
   Google Scholar
• Terpos E, Christoulas D, Kastritis E, Bone remodeling in patients with relapsed/refractory multiple myeloma who receive lenalidomide-based regimens. ASH Annual Meeting Abstracts. Blood 2007;110: abstract 4745
   Google Scholar
• Baz R, Walker E, Karam MA, Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006;17:1766-71
   PubMed Web of Science ®Google Scholar
• Knop S, Gerecke C, Liebisch P, Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009;113:4137-43
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Schey SA, Wu P, Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007;137:268-9
   PubMed Web of Science ®Google Scholar
• Reece DE, Masih-Khan E, Anglin P, Phase I/II trial of cyclophosphamide, prednisone, and lenalidomide for relapsed and refractory MM. Clin Lymphoma Myeloma 2009;9(Suppl 1):S53: abstract A333
   PubMedGoogle Scholar
• Siegel DS, Weber DM, Mitsiades C, Vorinostat/lenalidomide/dexamethasone: a phase I study. Clin Lymphoma Myeloma 2009;9(Suppl 1):S41-2: abstract A241
   Google Scholar
• Spencer A, Lonial S, Taylor K, Panobinostat and lenalidomide combination phase I trial in myeloma. Clin Lymphoma Myeloma 2009;9(Suppl 1):S52-3: abstract A329
   Google Scholar
• Raschko M, Markovina S, Miyamoto S, Phase II trial of bevacizumab combined with low dose dexamethasone and lenalidomide (BEV/REV/DEX) for relapsed or refractory myeloma (MM). ASH Annual Meeting Abstracts. Blood 2007;110: abstract 1173
   Google Scholar
• Jakubowiak AJ, Hideshima T, Sportelli P, Phase I trial of perifosine, lenalidomide, and dexamethasone in relapsed or refractory myeloma. Clin Lymphoma Myeloma 2009;9(Suppl 1):S56-7: abstract A347
   PubMedGoogle Scholar
• Lonial S, Singhal A, Jagannath S, Vij R. Phase Ib study of elotuzumab (HuLuc63) in combination with lenalidomide in relapsed multiple myeloma. Clin Lymphoma Myeloma 2009;9(Suppl 1):S20: abstract A129
   Google Scholar
• Jakubowiak AJ, Hofmeister C, Campagnaro E, Phase I/II trial of lenalidomide, bortezomib, doxil, and dexamethasone in front-line multiple myeloma. Clin Lymphoma Myeloma 2009;9(Suppl 1):S45-6: abstract A268
   Google Scholar
• Kumar S, Flinn IW, Noga SJ, Safety and efficacy of novel combination therapy with bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in newly diagnosed multiple myeloma: Initial results from the phase I/II multi-center EVOLUTION study. ASH Annual Meeting Abstracts. Blood 2008;112: abstract 3
   Google Scholar
• Kumar S, Hayman S, Buadi F, Phase II trial of lenalidomide (RevlimidTM) with cyclophosphamide and dexamethasone (RCd) for newly diagnosed myeloma. ASH Annual Meeting Abstracts. Blood 2008;112: abstract 91
   Google Scholar
• Richardson P, Lonial S, Jakubowiak A, Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study. ASH Annual Meeting Abstracts. Blood 2008;112: abstract 92
   Google Scholar
• Wang M, Delasalle K, Giralt S, Alexanian R. Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). ASH Annual Meeting Abstracts. Blood 2007;110: abstract 3611
   Google Scholar
• White DJ, Bahlis NJ, Marcellus DC, Phase II testing of lenalidomide plus melphalan for previously untreated older patients with multiple myeloma: the NCIC CTG MY.11 Trial. ASH Annual Meeting Abstracts. Blood 2008;112: abstract 2767
   Google Scholar
• Niesvizky R, Jayabalan DS, Christos PJ, BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008;111:1101-9
   PubMed Web of Science ®Google Scholar
• Palumbo A, Falco P, Corradini P, Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA‐Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459-65
   PubMed Web of Science ®Google Scholar
• Roy V, Stewart AK, Bergsagel PL, Phase II study of melphalan, prednisone and lenalidomide combination for newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation. ASH Annual Meeting Abstracts. Blood 2008;112: abstract 2769
   Google Scholar
• Palumbo A, Dimopoulos M, Delforge M, A phase III study to determine the efficacy and safety of lenalidomide in combination with mephlan and prednisone followed by lenalidomide (MPR-R) in patients ≥ 65 years with newly diagnosed multiple myeloma (NDMM). Presented at the 51st ASH Annual Meeting, New Orleans, Louisiana, USA, 5 – 8 December 2009
   Google Scholar
• Mateos MV, Lopez-Corraz L, Hernandez MT, A multicenter, randomized, open-label, phase III study of lenalidomide/dexamethasone versus therapeutic abstention in high-risk smoldering MM. Presented at the 51st ASH Annual Meeting, New Orleans, Louisiana, USA, 5 – 8 December 2009
   Google Scholar
• Kyle RA, Remstein ED, Therneau TM, Clinical course and prognosis of smolderly (asymptomatic) multiple myeloma. N Engl J Med 2007;356:2582-90
   PubMed Web of Science ®Google Scholar
• Perez-Persona E, Vidriales M-B, Mateo G, New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007;110:2586-92
   PubMed Web of Science ®Google Scholar
• Blade J, Dimopoulos M, Rosinol L, Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 2010;28:690-7
   Google Scholar
• Reece D, Song KW, Fu T, Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009;114:522-5
   PubMed Web of Science ®Google Scholar
• Kapoor P, Kumar S, Fonseca R, Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009;114:518-21
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Lonial S, Vesole DH, A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol 2007;5(Suppl 15):7-19
   PubMedGoogle Scholar
• Richardson PG, Blood E, Mitsiades CS, A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-64
   PubMed Web of Science ®Google Scholar
• Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 2006;95:924-30
   PubMed Web of Science ®Google Scholar
• Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006;354:2079-80
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Spencer A, Wang M, Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin. ASCO Meeting Abstracts. J Clin Oncol 2006;24(Suppl): abstract 7506
   Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA, Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-23
   PubMed Web of Science ®Google Scholar
• Zangari M, Fink L, Knight R, Effect on survival of lenalidomide and dexamethasone associated deep vein thrombosis (DVT) in relapsed multiple myeloma patients. Haematologica 2008;93(Suppl 1):256-7: abstract 0638
   Google Scholar
• Ishak J, Dimopoulos MA, Weber D, Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone. ASH Annual Meeting Abstracts. Blood 2008;112: abstract 3708
   Google Scholar
• Simpson L, Rajkumar SV, Dispenzieri A, High incidence of diarrhea in patients on long term therapy with lenalidomide and dexamethasone for multiple myeloma. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 30 May – 3 June, Chicago, IL, USA; 2008: abstract 8586
   Google Scholar